StockData

Allogene Therapeutics vs BioCardia

ALLO and BCDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALLO and BCDA compare

Allogene Therapeutics is the larger company, worth 22 times as much as BioCardia ($311M against $14.0M).

BioCardia scores higher on the StockData Score (5 against 3 for Allogene Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALLOBCDA
Size and price
Market cap$311M$14.0M
Share price$0.900$0.922
Change, 1 year−23.7%−28.6%
Change, 5 years−95.2%−97.2%
Beta (5Y)1.621.02
Employees15221
StockData Score
Total score35 (better)
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/B0.8× (better)5.2×
FCF yield−35.0% (better)−54.3%
Profitability
Return on equity−49.3% (better)−1803%
Return on invested capital−718%–
Financial health
Debt / equity–0.00
Interest coverage−142.5×–
Current ratio7.79 (better)2.09
Altman Z-score−4.92 (better)−51.20
Piotroski F-score33
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield–−86.7%
Shareholder yield0.00% (better)−86.7%
Ownership
Held by institutions90.5%8.8%
Held by insiders15.0%11.7%
Insider net buying, 12 months−$668K$170K (better)
Short interest, % of float17.5%5.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.